Oxford BioTherapeutics has entered a multi‑year collaboration with Bristol Myers Squibb to discover and develop novel T‑cell engager therapies for solid tumours, marking the company’s third major pharma partnership in 12 months.
The agreement will see OBT apply its OGAP‑Verify discovery and validation platform to identify tumour‑selective targets and generate next‑generation T‑cell engager molecules.
The company will also design and deliver development candidates, reflecting its expansion into a fully integrated discovery and preclinical development organisation. BMS will lead subsequent research, development and commercialisation.
Under the terms of the deal, OBT will receive an upfront payment inclusive of research funding, along with potential milestone payments and royalties on commercialised products. Financial details were not disclosed.
The collaboration follows partnerships signed with GSK and Roche in 2025, reinforcing growing industry confidence in OBT’s platform.
Christian Rohlff, Chief Executive Officer of OBT, said: “Collaborating with Bristol Myers Squibb, a global leader in oncology, represents an important milestone for OBT and underscores the momentum behind our partnerships with leading pharmaceutical companies.”
He added: “This new partnership builds on the proven strength of our platform to identify and validate highly differentiated, tumour-selective targets and reflects the growing confidence in our ability to translate that science into development-ready therapeutic candidates.
“By combining OGAP‑Verify’s discovery and validation capabilities with Bristol Myers Squibb’s expertise in translating oncology innovation into clinical and commercial outcomes, we are confident that together we can advance a new generation of innovative cancer therapies that have the potential to make a meaningful difference for patients.”
